Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model-Based Drug Development

  title={Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model-Based Drug Development},
  author={Lutz O. Harnisch and I Matthews and J. S. Chard and M O Karlsson},
  journal={CPT: Pharmacometrics \& Systems Pharmacology},
Model‐based drug development (MBDD) is accepted as a vital approach in understanding patients’ drug‐related benefit and risk by integrating quantitative information integration from diverse sources collected throughout drug development. 1 This perspective introduces the activities of the Drug and Disease Model Resources (DDMoRe) consortium, founded in 2011 through the Innovative Medicines Initiative Joint Undertaking (IMI‐JU) 2 as a European public–private partnership to address a lack of… 

Model‐based clinical drug development in the past, present and future: a commentary

A historical account of the use of model‐based drug development in clinical drug development, the current challenges and further opportunities for its application in the pharmaceutical industry are presented.

Model-Based Drug Development: Basics and Its Application

Basic of Model-Based Drug Development is introduced from the theoretical and the practical point of view with some examples and its application for the clinical drug development of the anti-diabetes drug is shown.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

PharmML, currently under development by the Drug Disease Model Resources (DDMoRe) consortium, is intended to become an exchange standard in pharmacometrics by providing means to encode models, trial designs, and modeling steps.

A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need

The outcome from a community survey and resulting analysis of how modelers view the impact and growth of QSP, how they utilize existing tools, and capabilities they need improved to further accelerate their impact on drug development are reported.

Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

The present review details how the emerging field of pharmacometrics can integrate medical record data with predictive pharmacological and statistical models of drug response to optimize and individualize therapies.

Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model‐Informed Drug Discovery and Development

Pharmacometric analyses are complex and multifactorial. It is essential to check, track, and document the vast amounts of data and metadata that are generated during these analyses (and the

Use of predictive models in CNS diseases.

  • R. Gomeni
  • Biology, Psychology
    Current opinion in pharmacology
  • 2014

The promises of quantitative systems pharmacology modelling for drug development

The Standard Output: A Tool‐Agnostic Modeling Storage Format

The Standard Output has been proposed as the tool-independent exchange and storage format for typical M&S results and shows its potential for enabling effective data flow across modelling tasks and facilitating information retrieval.



Model‐based Drug Development

What constitutes the key elements of MBDD and how these elements should fit together to inform drug development strategy and decision‐making are discussed.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.

The RICORDO approach to semantic interoperability for biomedical data and models: strategy, standards and solutions

RICORDO is contributing to the semantic interoperability of DMRs through ontology-based annotation by supporting more effective navigation and re-use of clinical D MRs, as well as sustaining interoperability operations based on the criterion of biological similarity.

strategy, standards and solutions

  • BMC Res. Notes 4, 313
  • 2011

Strategic Research Agenda , 2008 / 2011